EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin’s lymphoma

Charlotte Herzberg, Phillip Schiele, Anna Luzie Walter, Frederik Hamm, Benedikt Obermayer, Jonas Kath, David Busch, Andrea Stroux, Mareike Frick, Olaf Penack, Frederik Damm, Dimitrios L Wagner und 5 weitere

Journal for ImmunoTherapy of Cancer · 2025-04 · 13 (4) · e010709

DOI: 10.1136/jitc-2024-010709 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 09.04.2025. Verfasst von Charlotte Herzberg und 16 weiteren Autor:innen. Beteiligte Einrichtung: Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, T-Lymphocytes, Lymphoma, B-Cell, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ERC EpiTune, Novartis Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chimeric antigen receptor (CAR) T-cell therapy depends on T cells that are genetically modified to recognize and attack cancer cells. Their effectiveness thus hinges on the functionality of a patient’s own T cells. Since CAR T-cell therapy is currently only approved for advanced cancers after at least one line of chemotherapy, we evaluated the potential negative effects of prior exposure to chemotherapy on T-cell functionality.

Methods

We studied T cells of two B-cell non-Hodgkin’s lymphoma patient cohorts, one collected before treatment (pre-therapy) and the other after one or more (median 3) lines of chemotherapy (post-therapy). Leveraging advanced multiparameter flow cytometry, single-cell RNA sequencing (scRNA-seq), whole-genome DNA methylation arrays and in vitro functionality testing of generated CAR T cells, we compared patient samples in their suitability for effective CAR T-cell therapy.

Results

We discovered significant modifications in T-cell subsets and their transcriptional profiles secondary to chemotherapy exposure. Our analysis revealed a discernible shift towards phenotypically more differentiated T cells and an upregulation of markers indicative of T-cell exhaustion. Additionally, scRNA-seq and DNA methylation analyses revealed gene expression and epigenetic changes associated with diminished functionality in post-therapy T cells. Cytotoxicity assays demonstrated superior killing efficacy of CAR T cells derived from treatment-naïve patients compared with those with chemotherapy history.

Conclusions

These findings corroborate that employing T cells collected prior to frontline chemotherapy could enhance the effectiveness of CAR T-cell therapy and improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveT-LymphocytesLymphoma, B-CellReceptors, Chimeric AntigenHumansDNA MethylationMaleFemale

Stichwörter der Autor:innen

Adoptive cell therapy - ACTChimeric antigen receptor - CARLymphoma

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany.
  • BSIO Berlin School of Integrative Oncology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Department of Hematology, Oncology and Tumor Immunology, Charité University Hospital Berlin, Berlin, Germany.
  • Berlin Institute of Health at Charité, Universitätsmedizin Berlin, Core Unit Bioinformatics, Berlin, Germany.
  • Berlin Center for Advanced Therapies, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany, Berlin, Germany.
  • Institute for Biometrie and Clinical Epidemiology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Förderung

  • ERC EpiTune
  • Novartis Pharma

Zitieren

APA

Herzberg, C., Schiele, P., Walter, A. L., Hamm, F., Obermayer, B., Kath, J., Busch, D., Stroux, A., Frick, M., Penack, O., Damm, F., Wagner, D. L., Polansky, J., Bullinger, L., Künkele, A., Frentsch, M., & Na, I. K. (2025). Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin’s lymphoma. Journal for ImmunoTherapy of Cancer, 13(4), e010709. https://doi.org/10.1136/jitc-2024-010709

Vancouver

Herzberg C, Schiele P, Walter AL, Hamm F, Obermayer B, Kath J, et al. Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin’s lymphoma. Journal for ImmunoTherapy of Cancer. 2025;13(4):e010709. doi:10.1136/jitc-2024-010709

BibTeX
@article{Herzberg2025,
  author = {Herzberg, Charlotte and Schiele, Phillip and Walter, Anna Luzie and Hamm, Frederik and Obermayer, Benedikt and Kath, Jonas and Busch, David and Stroux, Andrea and Frick, Mareike and Penack, Olaf and Damm, Frederik and Wagner, Dimitrios L and Polansky, Julia and Bullinger, Lars and Künkele, Annette and Frentsch, Marco and Na, Il-Kang},
  title = {Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin’s lymphoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {4},
  pages = {e010709},
  doi = {10.1136/jitc-2024-010709}
}
Kostenlos starten →